

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 June 2021 (10.06.2021)



(10) International Publication Number
WO 2021/113754 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 38/08 (2019.01)
A61P 35/00 (2006.01) A61K 39/395 (2006.01)
A61K 31/57 (2006.01)

(21) International Application Number:

PCT/US2020/063468

(22) International Filing Date:

04 December 2020 (04.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/944,809	06 December 2019 (06.12.2019)	US
20315186.5	17 April 2020 (17.04.2020)	EP
63/023,198	11 May 2020 (11.05.2020)	US
63/037,353	10 June 2020 (10.06.2020)	US
63/094,833	21 October 2020 (21.10.2020)	US

(71) Applicants: **SANOFI** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR). **SANOFI-AVENTIS U.S. LLC** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **RISSE, Marie-Laure**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR). **ASSET, Gaele**; c/o Sanofi, 54, rue La Boétie, 75008 Paris (FR).

(74) Agent: **ONUFRIK, Christina et al.**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,


HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: USE OF ISATUXIMAB FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA



(57) Abstract: The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received one to three prior therapies (or prior lines of therapy) for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, carfilzomib, and dexamethasone.

WO 2021/113754 A1